BIA Separations, now part of Sartorius
BIA Separations, now part of Sartorius, develops and manufactures market leading CIM® monolithic chromatographic columns for purification and analysis of large biomolecules, such as viruses, plasmid DNA and mRNA, which are applied in cell and gene therapies. BIASep’s Cornerstone® Biomanufacturing Development Services are result of more than 20 years of hands-on experience with the most challenging biopharmaceutical products and offer a comprehensive approach of integrated process development solutions and novel technology designed to improve the robustness and yield of large biomolecules production, while improving the safety of therapeutic products. BIASep's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics; BIASep also has a keen presence with novel drug candidates in the clinical pipeline.
Role within Yscript
In Yscript, BIASep is part of Work Packages 3 and 4. BIA Sep will develop and produce laboratory and industrial-scale monolith chromatographic columns modified with oligonucleotides as well as standard monolithic columns, all of them utilized in the innovative mRNA downstream processing. A specific focus will be dedicated to the development and utilization of different analytical approaches with the focus on chromatography. These methods will be applied in the process analytical technology, what will be the part of an overall mRNA production platform.
Our vision for Yscript
BIASep constantly searches for novel and innovative purification strategies in the field of nucleic acid purification and further implements the gathered expertise in the industrial biotechnology business. BIASep´s core expertise is a development of chromatographic columns as well as downstream processes for large biomolecules, one of examples being messenger RNA. Therefore it is of great importance for BIASep to be part of Yscript consortium, because we can support the project with our knowledge and expertise in mRNA purification on a laboratory as well as on industrial scale. Urh Černigoj is leading the development of novel chromatographic columns, including their scaling up to the large formats. Rok Sekirnik has great expertise in setting up the whole purification process from the mRNA production stage to the final purified molecules, while Jana Vidič will contribute to the application of the analytical strategies for in-process and final qualification of mRNA.
